Financial Ratios Abbott Laboratories Swiss Exchange
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.00 CHF | +0.71% |
|
-2.07% | -28.28% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 7.8 | 7.61 | 6.11 | 6.06 | 6.63 | |||||
Return on Total Capital | 10.65 | 10.34 | 8.24 | 7.94 | 8.57 | |||||
Return On Equity % | 20.49 | 19.01 | 15.11 | 30.91 | 12.96 | |||||
Return on Common Equity | 20.53 | 19.05 | 15.14 | 30.95 | 13.03 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 58.06 | 56.28 | 55.32 | 55.56 | 56.66 | |||||
SG&A Margin | 25.55 | 24.52 | 25.89 | 26.48 | 26.24 | |||||
EBITDA Margin % | 29.61 | 28.36 | 26.09 | 25.54 | 27.15 | |||||
EBITA Margin % | 26.15 | 25.49 | 22.9 | 22.35 | 23.91 | |||||
EBIT Margin % | 21.4 | 20.88 | 18 | 17.87 | 20.12 | |||||
Income From Continuing Operations Margin % | 16.42 | 15.88 | 14.27 | 31.95 | 14.72 | |||||
Net Income Margin % | 16.42 | 15.88 | 14.27 | 31.95 | 14.72 | |||||
Net Avail. For Common Margin % | 16.35 | 15.82 | 14.21 | 31.83 | 14.66 | |||||
Normalized Net Income Margin | 12.67 | 12.45 | 10.76 | 10.64 | 12.32 | |||||
Levered Free Cash Flow Margin | 17.84 | 16.86 | 12.44 | 13.37 | 14.19 | |||||
Unlevered Free Cash Flow Margin | 18.61 | 17.66 | 13.43 | 14.2 | 14.88 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.58 | 0.58 | 0.54 | 0.54 | 0.53 | |||||
Fixed Assets Turnover | 4.26 | 4.28 | 3.72 | 3.65 | 3.59 | |||||
Receivables Turnover (Average Receivables) | 6.68 | 6.87 | 6.28 | 6.22 | 5.97 | |||||
Inventory Turnover (Average Inventory) | 3.55 | 3.37 | 2.81 | 2.92 | 3.03 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.85 | 1.63 | 1.64 | 1.67 | 1.58 | |||||
Quick Ratio | 1.28 | 1.06 | 1 | 1.05 | 1.02 | |||||
Operating Cash Flow to Current Liabilities | 0.8 | 0.62 | 0.52 | 0.6 | 0.58 | |||||
Days Sales Outstanding (Average Receivables) | 54.66 | 53.12 | 58.16 | 58.85 | 61.15 | |||||
Days Outstanding Inventory (Average Inventory) | 102.73 | 108.35 | 129.78 | 125.28 | 120.48 | |||||
Average Days Payable Outstanding | 83.72 | 81.86 | 88.7 | 85.05 | 78.93 | |||||
Cash Conversion Cycle (Average Days) | 73.67 | 79.61 | 99.25 | 99.08 | 102.71 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 53.44 | 48.63 | 40.88 | 32 | 26.79 | |||||
Total Debt / Total Capital | 34.83 | 32.72 | 29.02 | 24.24 | 21.13 | |||||
LT Debt/Equity | 50.67 | 41.9 | 37.47 | 28.33 | 20.52 | |||||
Long-Term Debt / Total Capital | 33.02 | 28.19 | 26.6 | 21.47 | 16.18 | |||||
Total Liabilities / Total Assets | 52.09 | 50.42 | 46.97 | 41.16 | 39.14 | |||||
EBIT / Interest Expense | 17.29 | 16.33 | 11.33 | 13.41 | 18.09 | |||||
EBITDA / Interest Expense | 24.61 | 22.82 | 16.98 | 19.82 | 25.2 | |||||
(EBITDA - Capex) / Interest Expense | 21.07 | 19.64 | 13.53 | 15.87 | 20.8 | |||||
Total Debt / EBITDA | 1.47 | 1.41 | 1.47 | 1.38 | 1.14 | |||||
Net Debt / EBITDA | 0.69 | 0.61 | 0.79 | 0.66 | 0.42 | |||||
Total Debt / (EBITDA - Capex) | 1.71 | 1.64 | 1.84 | 1.73 | 1.38 | |||||
Net Debt / (EBITDA - Capex) | 0.8 | 0.71 | 1 | 0.83 | 0.51 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 24.47 | 1.34 | -8.12 | 4.59 | 5.67 | |||||
Gross Profit, 1 Yr. Growth % | 26.61 | -1.7 | -9.69 | 5.03 | 7.77 | |||||
EBITDA, 1 Yr. Growth % | 41.86 | -2.84 | -15.48 | 2.4 | 12.31 | |||||
EBITA, 1 Yr. Growth % | 44.48 | -1.11 | -17.44 | 2.05 | 13.07 | |||||
EBIT, 1 Yr. Growth % | 62.72 | -0.99 | -20.77 | 3.82 | 18.96 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 58.15 | -1.95 | -17.45 | 134.18 | -51.32 | |||||
Net Income, 1 Yr. Growth % | 57.31 | -1.95 | -17.45 | 134.18 | -51.32 | |||||
Normalized Net Income, 1 Yr. Growth % | 68.41 | -0.28 | -20.6 | 3.43 | 19.97 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 58.23 | -0.76 | -16.62 | 134.36 | -51.31 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.14 | -4.15 | 5.58 | 5.48 | 14.5 | |||||
Inventory, 1 Yr. Growth % | 2.89 | 19.7 | 6.43 | -5.72 | 4.75 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -0.18 | 1.64 | 9.71 | 4.05 | 10.3 | |||||
Total Assets, 1 Yr. Growth % | 3.65 | -1.01 | -1.64 | 11.2 | 6.51 | |||||
Tangible Book Value, 1 Yr. Growth % | -97.08 | -2.14K | 77.95 | 193.16 | 26.02 | |||||
Common Equity, 1 Yr. Growth % | 9.21 | 2.47 | 5.23 | 23.47 | 9.37 | |||||
Cash From Operations, 1 Yr. Growth % | 33.31 | -9.04 | -24.21 | 17.86 | 11.78 | |||||
Capital Expenditures, 1 Yr. Growth % | -13.41 | -5.73 | 23.92 | 0.23 | -1.63 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 42.42 | -4.11 | -32.01 | 12.41 | 12.11 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 39.76 | -3.74 | -29.92 | 10.59 | 10.71 | |||||
Dividend Per Share, 1 Yr. Growth % | 18.95 | 5.49 | 8.33 | 7.69 | 7.14 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 16.2 | 12.31 | -3.5 | -1.97 | 5.13 | |||||
Gross Profit, 2 Yr. CAGR % | 15.73 | 11.95 | -5.78 | -2.61 | 6.39 | |||||
EBITDA, 2 Yr. CAGR % | 28.12 | 18.68 | -9.38 | -6.97 | 7.24 | |||||
EBITA, 2 Yr. CAGR % | 29.73 | 21.04 | -9.64 | -8.21 | 7.42 | |||||
EBIT, 2 Yr. CAGR % | 39.2 | 29.17 | -11.43 | -9.3 | 11.13 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 38.49 | 24.53 | -10.04 | 39.04 | 6.77 | |||||
Net Income, 2 Yr. CAGR % | 38.49 | 24.19 | -10.04 | 39.04 | 6.77 | |||||
Normalized Net Income, 2 Yr. CAGR % | 45.25 | 32.1 | -11.01 | -9.14 | 12.48 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 38.3 | 25.31 | -9.04 | 39.78 | 6.82 | |||||
Accounts Receivable, 2 Yr. CAGR % | 9.35 | -1.54 | 0.6 | 5.53 | 9.9 | |||||
Inventory, 2 Yr. CAGR % | 9.31 | 10.98 | 12.87 | 0.17 | -0.63 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.16 | 0.73 | 5.6 | 6.84 | 7.13 | |||||
Total Assets, 2 Yr. CAGR % | 5.25 | 1.29 | -1.33 | 4.58 | 8.83 | |||||
Tangible Book Value, 2 Yr. CAGR % | -86.44 | -22.69 | 503.02 | 128.4 | 92.21 | |||||
Common Equity, 2 Yr. CAGR % | 7.31 | 5.78 | 3.84 | 13.98 | 16.21 | |||||
Cash From Operations, 2 Yr. CAGR % | 31.02 | 10.12 | -16.97 | -5.49 | 14.78 | |||||
Capital Expenditures, 2 Yr. CAGR % | 7.28 | -9.65 | 8.08 | 11.44 | -0.71 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 41.4 | 18.19 | -19.37 | -12.58 | 12.26 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 37.15 | 17.22 | -17.97 | -11.96 | 10.65 | |||||
Dividend Per Share, 2 Yr. CAGR % | 17.42 | 12.02 | 6.9 | 8.01 | 7.42 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 12.1 | 11.02 | 5.04 | -0.88 | 0.51 | |||||
Gross Profit, 3 Yr. CAGR % | 11.83 | 9.58 | 4.22 | -2.31 | 0.74 | |||||
EBITDA, 3 Yr. CAGR % | 21.48 | 16.79 | 5.98 | -5.61 | -0.94 | |||||
EBITA, 3 Yr. CAGR % | 23.26 | 18.46 | 6.55 | -5.9 | -1.6 | |||||
EBIT, 3 Yr. CAGR % | 33.92 | 24.2 | 9.75 | -6.61 | -0.72 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 44.7 | 23.43 | 8.58 | 23.76 | -2.01 | |||||
Net Income, 3 Yr. CAGR % | 44 | 23.43 | 8.38 | 23.76 | -2.01 | |||||
Normalized Net Income, 3 Yr. CAGR % | 41.73 | 28.07 | 11.49 | -6.44 | 0.34 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 44.35 | 23.81 | 9.4 | 24.7 | -1.65 | |||||
Accounts Receivable, 3 Yr. CAGR % | 7.77 | 4.65 | 0.78 | 2.2 | 8.44 | |||||
Inventory, 3 Yr. CAGR % | 10.75 | 12.67 | 9.44 | 6.3 | 1.67 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 10.17 | 4.63 | 3.64 | 5.08 | 7.99 | |||||
Total Assets, 3 Yr. CAGR % | 3.83 | 3.12 | 0.31 | 2.68 | 5.22 | |||||
Tangible Book Value, 3 Yr. CAGR % | -75.68 | -27.83 | 2.07 | 374.16 | 87.33 | |||||
Common Equity, 3 Yr. CAGR % | 5.46 | 5.67 | 5.6 | 10.01 | 12.42 | |||||
Cash From Operations, 3 Yr. CAGR % | 18.69 | 16.01 | -2.78 | -6.69 | -0.05 | |||||
Capital Expenditures, 3 Yr. CAGR % | 10.58 | 2.75 | 0.38 | 5.4 | 6.9 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 16.65 | 24.18 | -1.79 | -9.92 | -5.02 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 14.38 | 21.84 | -1.33 | -9.38 | -4.98 | |||||
Dividend Per Share, 3 Yr. CAGR % | 16.2 | 13.3 | 10.78 | 7.17 | 7.72 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.61 | 9.77 | 5.58 | 5.63 | 5.08 | |||||
Gross Profit, 5 Yr. CAGR % | 16.27 | 9.09 | 4.41 | 4.53 | 5.08 | |||||
EBITDA, 5 Yr. CAGR % | 22.79 | 15.75 | 8.02 | 6.63 | 6.48 | |||||
EBITA, 5 Yr. CAGR % | 24.49 | 17.76 | 8.83 | 6.97 | 6.9 | |||||
EBIT, 5 Yr. CAGR % | 23.43 | 25.41 | 13.47 | 9.52 | 10.3 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 46.08 | 81.4 | 19.65 | 29.45 | 7.85 | |||||
Net Income, 5 Yr. CAGR % | 38.25 | 70.8 | 19.3 | 29.45 | 7.74 | |||||
Normalized Net Income, 5 Yr. CAGR % | 29.57 | 31.2 | 17.61 | 11.52 | 11.89 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 40.88 | 81.65 | 20 | 29.97 | 8.36 | |||||
Accounts Receivable, 5 Yr. CAGR % | 14.84 | 3.45 | 4.84 | 5 | 4.33 | |||||
Inventory, 5 Yr. CAGR % | 16.2 | 11.38 | 11.6 | 7.49 | 5.3 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 12.13 | 6.2 | 8.32 | 5.51 | 5.02 | |||||
Total Assets, 5 Yr. CAGR % | 7.38 | -0.48 | 1.74 | 3.7 | 3.63 | |||||
Tangible Book Value, 5 Yr. CAGR % | -54.18 | -25.13 | -12.15 | 14.42 | 31.48 | |||||
Common Equity, 5 Yr. CAGR % | 11.76 | 3.49 | 4.81 | 8.92 | 9.72 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.88 | 11.46 | 2.88 | 6.88 | 3.9 | |||||
Capital Expenditures, 5 Yr. CAGR % | 10.95 | 9.38 | 9.57 | 6.14 | -0.06 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 34.36 | 13.58 | 0.61 | 7.86 | 3.6 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 33.95 | 11.6 | 0.11 | 6.93 | 3.3 | |||||
Dividend Per Share, 5 Yr. CAGR % | 11.74 | 12.3 | 12.39 | 11.16 | 9.42 |
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Financials Abbott Laboratories
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















